Insmed's Brinsupri Launch Accelerates, Peak-Sales Target Raised to $14B
Q2 loss narrows sharply, Brinsupri guidance raised Insmed's Q2 net loss shrank to $13.2 million from $321.7 million a year earlier, and product revenue nearly quadrupled to $425.5 million. Brinsupri sales hit $309.2 million, up 49% from the prior quarter, and management raised 2026 Brinsupri guidance to $1.25–$1.40 billion. The stock jumped 33% on the news.
This is the period's biggest price-moving event and shows the core business is performing far better than expected.
Peak-sales estimate raised to over $14 billion Management now sees peak sales for its three lead programs exceeding $14 billion, a 75% increase. More than $7 billion is tied to already-launched Brinsupri, but over $6 billion depends on TPIP, which is still in Phase III trials for only two of four target indications. Insmed ended June with $1.2 billion in cash, enough to reach profitability in 2027 without raising capital.
This gives investors a long-term growth target and shows the company can fund itself, but also flags the pipeline risk.
Positive 12-month TPIP data supports Phase 3 launch Insmed reported positive 12-month data for TPIP in pulmonary arterial hypertension, with sustained improvements in exercise capacity and no new safety signals. This supports launching the PALM-PAH Phase 3 trial. TPIP is a key part of the $6 billion-plus peak-sales opportunity that still needs late-stage success.
It de-risks a major pipeline asset that underpins a large chunk of the raised peak-sales estimate.
EMBARC to run 3,000-patient brensocatib study The European bronchiectasis research group EMBARC will collaborate with Insmed on a 3,000-patient study of brensocatib (Brinsupri) across six countries. The study aims to show whether early treatment can change the disease course, which could expand use and strengthen the case for the drug beyond current approvals.
It signals strong clinical interest and potential for broader use, supporting long-term demand for the main growth driver.